Connect Sign In
A newly published epidemiologic study provides evidence for a previously unrecognized transfusion risk for patients with alpha-gal syndrome, an allergic condition that can develop after a tick bite.
The seven-part article series explores key provisions of the Enhancing CLIA Act and is intended to encourage thoughtful discussions about the future of regulating laboratory-developed tests.
ARUP Laboratories’ Infectious Disease Test Positivity Trends Dashboard now includes Cyclospora data to help clinicians and public health professionals monitor the rising cyclosporiasis outbreak.
ARUP CLARISPECT™ Multiple Myeloma MRD by Spectral Flow Cytometry characterizes neoplastic populations with greater confidence and sensitivity, while minimizing specimen volume requirements.
Karen Brisendine, the last of ARUP’s original 100 employees, retired after 42 years. Her career spanned multiple departments, reflecting a legacy of learning, adaptability, and service.
ARUP employees helped grant a Make-A-Wish® Utah child’s dream, transforming a lab into a supervillain’s playground and bringing joy to a family and community.
Join ARUP for the 3rd FDLC/ATLAS Course in Clinical Fungi, bringing global experts together for six days of hands-on training in fungal identification and current approaches to diagnosing and managing fungal diseases.
Newly introduced federal legislation would modernize oversight of lab-developed tests under the Clinical Laboratory Improvement Amendments but support innovation, transparency, and patient access.
Tracy George, MD, has been named one of the Top 10 Influential Women by Utah Business magazine, recognizing her leadership in advancing diagnostic innovation, science, and patient care.
After years of itchy, red bumps that made her skin feel as if ants were crawling across it, Misty Segrest has her life back—thanks in part to ultrasensitive laboratory testing and targeted treatment.
